Axon Enterprise (AXON)
(Delayed Data from NSDQ)
$318.55 USD
+1.80 (0.57%)
Updated May 3, 2024 04:00 PM ET
After-Market: $322.49 +3.94 (1.24%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth D Momentum D VGM
Brokerage Reports
Axon Enterprise, Inc [AXON]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Optimized Entry and Exit Levels for AXON 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Company: Axon Enterprise, Inc
Industry: Security and Safety Services
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
2019 May Give The First Peek Into the Gene Therapy Promise; Reit Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Long-term Data of ProSavin Looks Promising; Reit Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Licensing Deal Validates Commitment to New Vision and Strong Execution, We Believe
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Blank Check Thesis Yields Value as Company Reemerges From Slumber
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
An Update From the Diagnosis and Management of Lewy Body Dementia Webinar
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A